BioCardia's Heart Failure Trial Receives FDA Confirmation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 05 2026
0mins
Source: NASDAQ.COM
- FDA Confirmation: BioCardia's HF II trial has received FDA confirmation that it may support a Premarket Approval application, marking a significant advancement in the company's cardiac treatment efforts.
- Clinical Trial Design: The HF II trial aims to enroll 250 patients using a randomized, double-blind controlled design, with the primary endpoint assessing improvement in six-minute walk distance at 12 months, indicating potential treatment efficacy.
- Breakthrough Device Designation: The FDA has granted CardiAMP therapy a Breakthrough Device designation, intended to expedite review for technologies addressing serious unmet medical needs, further enhancing BioCardia's market prospects.
- Positive Market Reaction: BCDA stock has traded between $0.84 and $2.45 over the past year, closing at $0.91, with a pre-market increase of 22.87%, reflecting investor optimism regarding the therapy's potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BCDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BCDA
Wall Street analysts forecast BCDA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.948
Low
6.00
Averages
15.50
High
25.00
Current: 0.948
Low
6.00
Averages
15.50
High
25.00
No data
About BCDA
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BioCardia's Heart Failure Therapy Gains FDA Attention
- FDA Study Confirmation: BioCardia's CardiAMP Heart Failure study has received FDA confirmation that it could support a Premarket Approval application, indicating the therapy's potential in treating ischemic heart failure, which affects over one million patients in the U.S.
- Significant Stock Surge: BCDA shares surged over 50% in a single day following positive FDA indications, marking the largest single-day gain since August 2024 and breaching the 200-day moving average for the first time, reflecting strong market confidence in the company's future prospects.
- Retail Sentiment Shift: Retail sentiment for BCDA on Stocktwits flipped from 'bearish' to 'extremely bullish', with message volumes spiking, indicating investor anticipation for a 'huge breakthrough' in heart failure treatment, which may drive further investment interest.
- Japan Approval Plans: BioCardia is preparing to submit an approval application for its cell therapy in Japan in Q4 2026, demonstrating the company's strategic intent to expand into international markets and capitalize on growth opportunities in the global heart failure treatment landscape.
See More
BioCardia's Heart Failure Trial Receives FDA Confirmation
- FDA Confirmation: BioCardia's HF II trial has received FDA confirmation that it may support a Premarket Approval application, marking a significant advancement in the company's cardiac treatment efforts.
- Clinical Trial Design: The HF II trial aims to enroll 250 patients using a randomized, double-blind controlled design, with the primary endpoint assessing improvement in six-minute walk distance at 12 months, indicating potential treatment efficacy.
- Breakthrough Device Designation: The FDA has granted CardiAMP therapy a Breakthrough Device designation, intended to expedite review for technologies addressing serious unmet medical needs, further enhancing BioCardia's market prospects.
- Positive Market Reaction: BCDA stock has traded between $0.84 and $2.45 over the past year, closing at $0.91, with a pre-market increase of 22.87%, reflecting investor optimism regarding the therapy's potential.
See More
BioCardia Receives FDA Meeting Minutes Supporting Heart Failure Treatment
- FDA Meeting Confirmation: BioCardia's CardiAMP Cell Therapy System received confirmation during the Q-Sub meeting with the FDA, indicating that the ongoing Heart Failure II Trial may support market approval, potentially benefiting over one million patients in the U.S.
- Breakthrough Therapy Designation: CardiAMP has been granted FDA Breakthrough Therapy designation, utilizing patients' own bone marrow cells in a minimally invasive procedure aimed at increasing myocardial microvascular density and reducing tissue fibrosis, showcasing significant clinical potential.
- International Approval Prospects: The Japan Pharmaceutical and Medical Device Agency indicated that results from three completed clinical trials for CardiAMP in treating heart failure likely provide sufficient evidence of safety and efficacy for a successful submission, enhancing BioCardia's international market opportunities.
- Clinical Trial Support: The clinical development of this therapy is supported by the Maryland Stem Cell Research Fund and is reimbursed by the Centers for Medicare and Medicaid Services, highlighting its importance and potential market value within the healthcare system.
See More
BioCardia Receives Consultation Record from Japan's PDMA for CardiAMP Approval
- Regulatory Support: BioCardia Inc. has received a Consultation Record from Japan's Pharmaceutical and Medical Devices Agency (PDMA) to support the regulatory approval of CardiAMP cell therapy for ischemic heart failure, marking a significant step in the company's international expansion.
- Therapy Background: CardiAMP is a cell therapy that delivers a patient's own bone marrow cells to the heart via a catheter to increase capillary density and reduce tissue fibrosis, having previously received breakthrough designation from the U.S. FDA, indicating its potential in treating heart diseases.
- Market Access Requirements: The PDMA has requested BioCardia to provide post-marketing supply plans, patient selection criteria, clinical decision-making frameworks, and appropriate medical infrastructure and specialist involvement, which will impact the market access process for CardiAMP.
- Clinical Trial Support: BioCardia will support its submission to the PDMA with positive outcomes from three clinical trials demonstrating CardiAMP's effectiveness in reducing elevated biomarkers linked to heart stress and the incidence of heart failure, with the review process expected to take approximately seven months.
See More
BioCardia Secures FDA Breakthrough Designation and Medicare Reimbursement
- FDA Breakthrough Designation: BioCardia has received FDA breakthrough designation for its cardiac cell therapy, which is expected to enhance market acceptance and patient willingness to undergo treatment, especially with Medicare reimbursement set at $20,000 per procedure.
- Positive Clinical Trial Signals: The CARDIAMP heart failure trial has shown statistically significant improvements in heart function and quality of life for treated patients, indicating the therapy's potential impact in the cardiac treatment landscape.
- Japanese Market Opportunity: Japan's Pharmaceutical and Medical Devices Agency is inclined to accept BioCardia's data for regulatory submission, with an initial market opportunity targeting approximately 20,000 patients, providing a strategic direction for future growth despite limited immediate revenue potential.
- Effective Financial Management: BioCardia's financial management has led to a decrease in total expenses by $460,000 to $2.3 million in Q1, although cash and cash equivalents stand at only $951,000, reflecting the company's ongoing challenges in balancing cost control with operational needs.
See More
BioCardia Q1 2026 Earnings Call Highlights
- FDA Breakthrough Progress: BioCardia's CardiAMP cell therapy has received FDA breakthrough designation, with Medicare reimbursement currently set at $20,000 per treatment, which is expected to significantly enhance market acceptance and drive revenue growth.
- Japanese Regulatory Advancement: Following a formal consultation with Japan's PMDA, BioCardia received feedback indicating a willingness to accept existing data, with plans to submit the Shonin application in approximately seven months, further expanding its international market presence.
- Improved Financial Position: The company reported a net loss of $2.3 million for Q1 2026, with cash used in operations at $1.7 million, decreasing from $2.5 million in the previous quarter, indicating initial success in cost control measures.
- Market Opportunity Assessment: With around 300,000 patients suffering from ischemic heart failure in Japan, BioCardia anticipates an initial addressable patient population of about 20,000, suggesting a potential market size of $400 million based on the $20,000 reimbursement in the U.S., highlighting strong commercial prospects.
See More
BioCardia's Heart Failure Therapy Gains FDA Attention
- FDA Study Confirmation: BioCardia's CardiAMP Heart Failure study has received FDA confirmation that it could support a Premarket Approval application, indicating the therapy's potential in treating ischemic heart failure, which affects over one million patients in the U.S.
- Significant Stock Surge: BCDA shares surged over 50% in a single day following positive FDA indications, marking the largest single-day gain since August 2024 and breaching the 200-day moving average for the first time, reflecting strong market confidence in the company's future prospects.
- Retail Sentiment Shift: Retail sentiment for BCDA on Stocktwits flipped from 'bearish' to 'extremely bullish', with message volumes spiking, indicating investor anticipation for a 'huge breakthrough' in heart failure treatment, which may drive further investment interest.
- Japan Approval Plans: BioCardia is preparing to submit an approval application for its cell therapy in Japan in Q4 2026, demonstrating the company's strategic intent to expand into international markets and capitalize on growth opportunities in the global heart failure treatment landscape.
See More
BioCardia's Heart Failure Trial Receives FDA Confirmation
- FDA Confirmation: BioCardia's HF II trial has received FDA confirmation that it may support a Premarket Approval application, marking a significant advancement in the company's cardiac treatment efforts.
- Clinical Trial Design: The HF II trial aims to enroll 250 patients using a randomized, double-blind controlled design, with the primary endpoint assessing improvement in six-minute walk distance at 12 months, indicating potential treatment efficacy.
- Breakthrough Device Designation: The FDA has granted CardiAMP therapy a Breakthrough Device designation, intended to expedite review for technologies addressing serious unmet medical needs, further enhancing BioCardia's market prospects.
- Positive Market Reaction: BCDA stock has traded between $0.84 and $2.45 over the past year, closing at $0.91, with a pre-market increase of 22.87%, reflecting investor optimism regarding the therapy's potential.
See More
BioCardia Receives FDA Meeting Minutes Supporting Heart Failure Treatment
- FDA Meeting Confirmation: BioCardia's CardiAMP Cell Therapy System received confirmation during the Q-Sub meeting with the FDA, indicating that the ongoing Heart Failure II Trial may support market approval, potentially benefiting over one million patients in the U.S.
- Breakthrough Therapy Designation: CardiAMP has been granted FDA Breakthrough Therapy designation, utilizing patients' own bone marrow cells in a minimally invasive procedure aimed at increasing myocardial microvascular density and reducing tissue fibrosis, showcasing significant clinical potential.
- International Approval Prospects: The Japan Pharmaceutical and Medical Device Agency indicated that results from three completed clinical trials for CardiAMP in treating heart failure likely provide sufficient evidence of safety and efficacy for a successful submission, enhancing BioCardia's international market opportunities.
- Clinical Trial Support: The clinical development of this therapy is supported by the Maryland Stem Cell Research Fund and is reimbursed by the Centers for Medicare and Medicaid Services, highlighting its importance and potential market value within the healthcare system.
See More
BioCardia Receives Consultation Record from Japan's PDMA for CardiAMP Approval
- Regulatory Support: BioCardia Inc. has received a Consultation Record from Japan's Pharmaceutical and Medical Devices Agency (PDMA) to support the regulatory approval of CardiAMP cell therapy for ischemic heart failure, marking a significant step in the company's international expansion.
- Therapy Background: CardiAMP is a cell therapy that delivers a patient's own bone marrow cells to the heart via a catheter to increase capillary density and reduce tissue fibrosis, having previously received breakthrough designation from the U.S. FDA, indicating its potential in treating heart diseases.
- Market Access Requirements: The PDMA has requested BioCardia to provide post-marketing supply plans, patient selection criteria, clinical decision-making frameworks, and appropriate medical infrastructure and specialist involvement, which will impact the market access process for CardiAMP.
- Clinical Trial Support: BioCardia will support its submission to the PDMA with positive outcomes from three clinical trials demonstrating CardiAMP's effectiveness in reducing elevated biomarkers linked to heart stress and the incidence of heart failure, with the review process expected to take approximately seven months.
See More
BioCardia Secures FDA Breakthrough Designation and Medicare Reimbursement
- FDA Breakthrough Designation: BioCardia has received FDA breakthrough designation for its cardiac cell therapy, which is expected to enhance market acceptance and patient willingness to undergo treatment, especially with Medicare reimbursement set at $20,000 per procedure.
- Positive Clinical Trial Signals: The CARDIAMP heart failure trial has shown statistically significant improvements in heart function and quality of life for treated patients, indicating the therapy's potential impact in the cardiac treatment landscape.
- Japanese Market Opportunity: Japan's Pharmaceutical and Medical Devices Agency is inclined to accept BioCardia's data for regulatory submission, with an initial market opportunity targeting approximately 20,000 patients, providing a strategic direction for future growth despite limited immediate revenue potential.
- Effective Financial Management: BioCardia's financial management has led to a decrease in total expenses by $460,000 to $2.3 million in Q1, although cash and cash equivalents stand at only $951,000, reflecting the company's ongoing challenges in balancing cost control with operational needs.
See More
BioCardia Q1 2026 Earnings Call Highlights
- FDA Breakthrough Progress: BioCardia's CardiAMP cell therapy has received FDA breakthrough designation, with Medicare reimbursement currently set at $20,000 per treatment, which is expected to significantly enhance market acceptance and drive revenue growth.
- Japanese Regulatory Advancement: Following a formal consultation with Japan's PMDA, BioCardia received feedback indicating a willingness to accept existing data, with plans to submit the Shonin application in approximately seven months, further expanding its international market presence.
- Improved Financial Position: The company reported a net loss of $2.3 million for Q1 2026, with cash used in operations at $1.7 million, decreasing from $2.5 million in the previous quarter, indicating initial success in cost control measures.
- Market Opportunity Assessment: With around 300,000 patients suffering from ischemic heart failure in Japan, BioCardia anticipates an initial addressable patient population of about 20,000, suggesting a potential market size of $400 million based on the $20,000 reimbursement in the U.S., highlighting strong commercial prospects.
See More
